HealthDay - FRIDAY, Nov. 18 (HealthDay News) -- Erwinaze (asparaginase Erwinia chrysanthemi) has been approved by the U.S. Food and Drug Administration to treat Acute Lymphoblastic Leukemia (ALL) among people who have developed an allergy to more standard treatments.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.